Does the media prefer CNTA or ANAB?

In the previous week, AnaptysBio had 9 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 12 mentions for AnaptysBio and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.77 beat AnaptysBio's score of 1.44 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MIRM or ANAB?

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than AnaptysBio. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 12 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.44 beat Mirum Pharmaceuticals' score of 1.20 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANAB or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Belite Bio's return on equity of -13.14% beat AnaptysBio's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% -1,101.24% -7.75% Belite Bio N/A -13.14% -12.88%

Does the media favor ANAB or BLTE?

In the previous week, AnaptysBio had 9 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for AnaptysBio and 3 mentions for Belite Bio. AnaptysBio's average media sentiment score of 1.44 beat Belite Bio's score of 0.47 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ANAB or COGT?

In the previous week, AnaptysBio had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for AnaptysBio and 9 mentions for Cogent Biosciences. AnaptysBio's average media sentiment score of 1.44 beat Cogent Biosciences' score of 0.69 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANAB or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Scholar Rock's return on equity of -163.52% beat AnaptysBio's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% -1,101.24% -7.75% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to ANAB or SRRK?

In the previous week, AnaptysBio had 4 more articles in the media than Scholar Rock. MarketBeat recorded 12 mentions for AnaptysBio and 8 mentions for Scholar Rock. AnaptysBio's average media sentiment score of 1.44 beat Scholar Rock's score of 1.34 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AnaptysBio (ANAB) Competitors

$56.07 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$56.14 +0.06 (+0.12%)

As of 06/12/2026 06:48 PM Eastern

Compare

ANAB vs. CNTA, MIRM, BLTE, COGT, and SRRK

Should you buy AnaptysBio stock or one of its competitors? MarketBeat compares AnaptysBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AnaptysBio include Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), Belite Bio (BLTE), Cogent Biosciences (COGT), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does AnaptysBio compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Centessa Pharmaceuticals currently has a consensus target price of $41.33, indicating a potential upside of 4.06%. AnaptysBio has a consensus target price of $81.82, indicating a potential upside of 45.92%. Given AnaptysBio's stronger consensus rating and higher possible upside, analysts clearly believe AnaptysBio is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 33.5% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, AnaptysBio had 9 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 12 mentions for AnaptysBio and 3 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.77 beat AnaptysBio's score of 1.44 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Centessa Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Centessa Pharmaceuticals' return on equity of -60.37% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
AnaptysBio	-11.53%	-1,101.24%	-7.75%

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Centessa Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	409.54	-$197.53M	-$1.79	N/A
AnaptysBio	$234.60M	6.95	-$13.23M	-$1.08	N/A

Summary

AnaptysBio beats Centessa Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does AnaptysBio compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

AnaptysBio has lower revenue, but higher earnings than Mirum Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.62	-$23.36M	-$13.61	N/A
AnaptysBio	$234.60M	6.95	-$13.23M	-$1.08	N/A

In the previous week, Mirum Pharmaceuticals had 2 more articles in the media than AnaptysBio. MarketBeat recorded 14 mentions for Mirum Pharmaceuticals and 12 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.44 beat Mirum Pharmaceuticals' score of 1.20 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals presently has a consensus target price of $138.36, suggesting a potential upside of 39.26%. AnaptysBio has a consensus target price of $81.82, suggesting a potential upside of 45.92%. Given AnaptysBio's higher probable upside, analysts clearly believe AnaptysBio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

AnaptysBio has a net margin of -11.53% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
AnaptysBio	-11.53%	-1,101.24%	-7.75%

Summary

Mirum Pharmaceuticals beats AnaptysBio on 9 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Belite Bio?

AnaptysBio (NASDAQ:ANAB) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

AnaptysBio currently has a consensus price target of $81.82, suggesting a potential upside of 45.92%. Belite Bio has a consensus price target of $203.00, suggesting a potential upside of 46.93%. Given Belite Bio's higher possible upside, analysts clearly believe Belite Bio is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

AnaptysBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, meaning that its share price is 224% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.95	-$13.23M	-$1.08	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

0.5% of Belite Bio shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, AnaptysBio had 9 more articles in the media than Belite Bio. MarketBeat recorded 12 mentions for AnaptysBio and 3 mentions for Belite Bio. AnaptysBio's average media sentiment score of 1.44 beat Belite Bio's score of 0.47 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Belite Bio's return on equity of -13.14% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	-1,101.24%	-7.75%
Belite Bio	N/A	-13.14%	-12.88%

Summary

AnaptysBio beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Cogent Biosciences?

AnaptysBio (NASDAQ:ANAB) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

AnaptysBio has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than Cogent Biosciences. AnaptysBio is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.95	-$13.23M	-$1.08	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, AnaptysBio had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 12 mentions for AnaptysBio and 9 mentions for Cogent Biosciences. AnaptysBio's average media sentiment score of 1.44 beat Cogent Biosciences' score of 0.69 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio presently has a consensus price target of $81.82, indicating a potential upside of 45.92%. Cogent Biosciences has a consensus price target of $43.73, indicating a potential upside of 32.11%. Given AnaptysBio's higher possible upside, equities research analysts plainly believe AnaptysBio is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Cogent Biosciences' return on equity of -104.27% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	-1,101.24%	-7.75%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

AnaptysBio beats Cogent Biosciences on 9 of the 14 factors compared between the two stocks.

How does AnaptysBio compare to Scholar Rock?

AnaptysBio (NASDAQ:ANAB) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

AnaptysBio has higher revenue and earnings than Scholar Rock. AnaptysBio is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.95	-$13.23M	-$1.08	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

In the previous week, AnaptysBio had 4 more articles in the media than Scholar Rock. MarketBeat recorded 12 mentions for AnaptysBio and 8 mentions for Scholar Rock. AnaptysBio's average media sentiment score of 1.44 beat Scholar Rock's score of 1.34 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Scholar Rock's return on equity of -163.52% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	-1,101.24%	-7.75%
Scholar Rock	N/A	-163.52%	-96.67%

91.1% of Scholar Rock shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by company insiders. Comparatively, 13.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AnaptysBio currently has a consensus price target of $81.82, indicating a potential upside of 45.92%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 26.75%. Given AnaptysBio's higher probable upside, research analysts clearly believe AnaptysBio is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

AnaptysBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

AnaptysBio beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANAB vs. The Competition

Export

Metric	AnaptysBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.63B	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-51.92	19.82	24.21	24.42
Price / Sales	6.95	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	41.84	8.32	10.66	6.83
Net Income	-$13.23M	$23.94M	$3.57B	$337.67M
7 Day Performance	9.17%	1.84%	0.58%	1.17%
1 Month Performance	-11.21%	-0.04%	1.54%	3.16%
1 Year Performance	140.44%	44.82%	25.40%	30.58%

AnaptysBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANAB AnaptysBio	3.523 of 5 stars	$56.07 flat	$81.82 +45.9%	+140.4%	$1.63B	$234.60M	N/A	100	Positive News Analyst Forecast Analyst Revision
CNTA Centessa Pharmaceuticals	1.7888 of 5 stars	$39.69 -0.2%	$41.33 +4.1%	+220.8%	$5.93B	$15M	N/A	200	Positive News
MIRM Mirum Pharmaceuticals	4.122 of 5 stars	$94.00 -1.6%	$137.64 +46.4%	+100.2%	$5.82B	$521.31M	N/A	140	News Coverage Positive News Analyst Forecast Insider Trade
BLTE Belite Bio	2.7366 of 5 stars	$136.62 -3.4%	$203.00 +48.6%	+132.0%	$5.67B	N/A	N/A	10
COGT Cogent Biosciences	2.6664 of 5 stars	$31.38 -1.9%	$43.73 +39.3%	+367.5%	$5.46B	N/A	N/A	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANAB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Competitors

ANAB vs. CNTA, MIRM, BLTE, COGT, and SRRK

How does AnaptysBio compare to Centessa Pharmaceuticals?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Summary

How does AnaptysBio compare to Belite Bio?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Summary

How does AnaptysBio compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Competitors

ANAB vs. CNTA, MIRM, BLTE, COGT, and SRRK

How does AnaptysBio compare to Centessa Pharmaceuticals?

Do analysts rate CNTA or ANAB?

Do insiders & institutionals have more ownership in CNTA or ANAB?

Does the media prefer CNTA or ANAB?

Is CNTA or ANAB more profitable?

Which has more volatility and risk, CNTA or ANAB?

Which has higher valuation & earnings, CNTA or ANAB?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Which has more volatility and risk, MIRM or ANAB?

Which has higher valuation and earnings, MIRM or ANAB?

Does the media refer more to MIRM or ANAB?

Do analysts recommend MIRM or ANAB?

Is MIRM or ANAB more profitable?

Summary

How does AnaptysBio compare to Belite Bio?

Do analysts recommend ANAB or BLTE?

Which has more volatility & risk, ANAB or BLTE?

Which has preferable earnings & valuation, ANAB or BLTE?

Do institutionals & insiders hold more shares of ANAB or BLTE?

Does the media favor ANAB or BLTE?

Is ANAB or BLTE more profitable?

Summary

How does AnaptysBio compare to Cogent Biosciences?

Which has more volatility and risk, ANAB or COGT?

Which has higher earnings and valuation, ANAB or COGT?

Does the media prefer ANAB or COGT?

Do analysts rate ANAB or COGT?

Is ANAB or COGT more profitable?

Summary

How does AnaptysBio compare to Scholar Rock?

Which has preferable earnings and valuation, ANAB or SRRK?

Does the media refer more to ANAB or SRRK?

Is ANAB or SRRK more profitable?

Do insiders & institutionals have more ownership in ANAB or SRRK?

Do analysts recommend ANAB or SRRK?

Which has more risk and volatility, ANAB or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools